Article Information
Published By
Online ISSN
History
- Received July 12, 2022
- Accepted December 17, 2022
- Published online January 26, 2023.
Article Versions
- You are currently viewing a previous version of this article (January 26, 2023 - 07:34).
- View the most recent version of this article
Copyright & Usage
Copyright ©The authors 2023 This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions@ersnet.org
Author Information
- Helen Marshall1⇑,
- Jim M. Wild1,
- Laurie J. Smith1,
- Latife Hardaker2,
- Titti Fihn-Wikander3,
- Hana Müllerová4 and
- Rod Hughes5
- for the NOVELTY study investigators
- 1POLARIS, Dept of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, UK
- 2Priory Medical Group, York, UK
- 3Evidence Delivery, BioPharmaceuticals Medical, AstraZeneca, Gothenburg, Sweden
- 4Respiratory & Immunology, Medical and Payer Evidence Strategy, BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK
- 5External Scientific Engagement, BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK
- Corresponding author: Helen Marshall (h.marshall{at}sheffield.ac.uk)
Funding
AstraZeneca